Bladder Cancer

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the disease.

Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.

Treatment with a custom-made vaccine combination was found to be safe and feasible for patients with bladder cancer, eliciting a strong immune response.

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for some with bladder cancer.

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.

Patient and disease-related factors influence surgical recovery and treatment outcomes after Keytruda and Padcev in advanced urothelial cancer.

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study.

Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety.

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.

Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer following cystectomy and chemotherapy.

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder cancer, based on the NIAGARA trial.

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Bavencio as first-line maintenance was associated with long-term efficacy in advanced urothelial carcinoma regardless of patients’ diabetes status.

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ

In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines.

Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.

Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in high-risk bladder cancer.

Antihistamines are associated with improvement for patients with metastatic urothelial carcinoma receiving Tecentriq.

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin in the U.S.

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.

My pet provided emotional support and helped me tolerate chemotherapy better, reducing my stress and improving my well-being throughout my cancer journey.